Ascletis Pharma Inc. (1672.HK)
HKD 2.55
(-10.21%)
HKD 2.55
(-10.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -144.16 Million | -142.45 Million | -146.93 Million | -84.91 Million | -74.34 Million | -96.59 Million |
| Net Income | -144.71 Million | -314.84 Million | -199.01 Million | -209.24 Million | -95.96 Million | -19.87 Million |
| Depreciation & Amortization | 18.48 Million | 30.19 Million | 29.54 Million | 27.16 Million | 22.14 Million | 11.98 Million |
| Deferred income taxes | - | - | 47.53 Million | 122.46 Million | 76.66 Million | -1.8 Million |
| Stock-based compensation | 1.33 Million | 3.19 Million | 7.13 Million | 4.61 Million | 3.12 Million | 4.26 Million |
| Change in working capital | 34.45 Million | 33.8 Million | -10.17 Million | 10.42 Million | -8.41 Million | -66.15 Million |
| Other non-cash items | -98.83 Million | 105.19 Million | -21.95 Million | -40.33 Million | -71.89 Million | -25 Million |
| Investing Cash Flow | 149.84 Million | -1.29 Billion | -274.49 Million | 132.29 Million | 602.26 Million | -817.47 Million |
| Investments in PPE | -19.15 Million | -14.4 Million | -7.19 Million | -38.96 Million | -28.23 Million | -60.08 Million |
| Acquisitions | - | - | 2.23 Million | -19.65 Million | -67.4 Million | -44.26 Million |
| Investment purchases | -997.22 Million | -1.76 Billion | -601.97 Million | -75.41 Million | 9.34 Million | -1.13 Billion |
| Sales/Maturities of investments | 1.16 Billion | 479.32 Million | 332.2 Million | 190.61 Million | 697.23 Million | 372 Million |
| Other Investing Activities | 156.05 Million | 92 Thousand | 254 Thousand | 75.71 Million | -8.68 Million | 47.45 Million |
| Financing Cash Flow | -81.49 Million | -1.41 Million | -31.09 Million | -21.67 Million | -48.21 Million | 2.56 Billion |
| Debt repayment | -2.39 Million | -2.22 Million | -2.28 Million | -1.93 Million | -1.94 Million | - |
| Dividends payments | - | - | - | - | - | -57.81 Million |
| Common Stock Repurchased | -78.96 Million | - | -28.68 Million | -19.6 Million | -46.26 Million | - |
| Common Stock Issuance | - | 961 Thousand | - | - | - | 2.97 Billion |
| Other Financing Activities | -144 Thousand | -157 Thousand | -125 Thousand | -135 Thousand | -48.21 Million | -352.82 Million |
| Accounts receivables | 18.44 Million | 29.74 Million | -26.99 Million | 42.98 Million | -11.9 Million | -57.62 Million |
| Accounts payables | - | -29.74 Million | 26.99 Million | -42.98 Million | 11.9 Million | - |
| Inventory | -8.05 Million | -12.83 Million | -5.06 Million | -18.37 Million | -2.16 Million | -21.66 Million |
| Other working capital | 28.13 Million | 46.64 Million | -5.1 Million | 28.79 Million | -6.25 Million | -44.49 Million |
| Cash at beginning of period | 403.76 Million | 1.72 Billion | 2.21 Billion | 2.29 Billion | 1.78 Billion | 123.69 Million |
| Cash at end of period | 330.11 Million | 403.76 Million | 1.72 Billion | 2.21 Billion | 2.29 Billion | 1.78 Billion |
| Capital Expenditure | -19.15 Million | -14.4 Million | -7.19 Million | -38.96 Million | -28.23 Million | -60.08 Million |
| Effect of forex changes on cash | 2.16 Million | 117.61 Million | -30.57 Million | -110.25 Million | 33.44 Million | 12.11 Million |
| Net cash flow / Change in cash | -73.65 Million | -1.32 Billion | -483.09 Million | -84.54 Million | 513.15 Million | 1.65 Billion |
| Free Cash Flow | -163.32 Million | -156.85 Million | -154.12 Million | -123.87 Million | -102.57 Million | -156.67 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -65.15 Million | -65.15 Million | -64.07 Million | -144.71 Million | -64.07 Million | -8.27 Million |
| Depreciation & Amortization | 5.16 Million | 5.16 Million | 5.64 Million | 18.48 Million | 4 Million | 4.38 Million |
| Deferred income taxes | - | - | - | - | - | -4 Million |
| Stock-based compensation | 833 Thousand | 833 Thousand | -298.5 Thousand | 1.33 Million | -298.5 Thousand | 964 Thousand |
| Change in working capital | - | - | 26.63 Million | 34.45 Million | 26.63 Million | -7.37 Million |
| Other non-cash items | -42.54 Million | -42.54 Million | -6 Million | -98.83 Million | -4.36 Million | -23.67 Million |
| Investing Cash Flow | 130.81 Million | 130.81 Million | 4.08 Million | 149.84 Million | 4.08 Million | 70.84 Million |
| Investments in PPE | - | - | -2.18 Million | -19.15 Million | -2.18 Million | -924.5 Thousand |
| Acquisitions | - | - | - | - | - | 5654.76 |
| Investment purchases | - | - | - | -997.22 Million | - | -570 Million |
| Sales/Maturities of investments | - | - | - | 1.16 Billion | - | 728.19 Million |
| Other Investing Activities | 130.81 Million | 130.81 Million | 6.26 Million | 156.05 Million | 6.26 Million | 71.76 Million |
| Financing Cash Flow | -22.72 Million | -22.72 Million | -35.04 Million | -81.49 Million | -35.04 Million | -5.69 Million |
| Debt repayment | - | - | - | -2.39 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -34.45 Million | -78.96 Million | -34.45 Million | -5.02 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -22.72 Million | -22.72 Million | -590 Thousand | -144 Thousand | -590 Thousand | -677.5 Thousand |
| Accounts receivables | - | - | 100.5 Thousand | 18.44 Million | 100.5 Thousand | 9.12 Million |
| Accounts payables | - | - | - | - | - | 4.31 Million |
| Inventory | - | - | -575.5 Thousand | -8.05 Million | -575.5 Thousand | -3.45 Million |
| Other working capital | - | - | 27.11 Million | 28.13 Million | 27.11 Million | -13.04 Million |
| Cash at beginning of period | - | - | - | 403.76 Million | - | 2.77 Billion |
| Cash at end of period | 6.43 Million | 6.43 Million | -69.78 Million | 330.11 Million | -69.78 Million | 2.71 Billion |
| Capital Expenditure | - | - | -2.18 Million | -19.15 Million | -2.18 Million | -924.5 Thousand |
| Effect of forex changes on cash | 57 Thousand | 57 Thousand | -718 Thousand | 2.16 Million | -718 Thousand | 1.79 Million |
| Net cash flow / Change in cash | 6.43 Million | 6.43 Million | -69.78 Million | -73.65 Million | -69.78 Million | -63.13 Million |
| Free Cash Flow | -101.7 Million | -101.7 Million | -40.28 Million | -163.32 Million | -40.28 Million | -34.9 Million |
MAHESHWARI
AZURF
PXA
OAL
HEWA
MNDP